Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Subscribe To Our Newsletter & Stay Updated
